Gainers

• InMed Pharmaceuticals (NASDAQ:INM) stock moved upwards by 66.8% to $2.57 during Wednesday's pre-market session. The company's market cap stands at $8.2 million.
• China SXT Pharmaceuticals (NASDAQ:SXTC) shares increased by 57.46% to $4.22. The company's market cap stands at $102.4 million.
• Lakewood-Amedex (NASDAQ:LABT) stock increased by 43.46% to $2.67. The market value of their outstanding shares is at $3.2 million.
• Advanced Biomed (NASDAQ:ADVB) shares increased by 24.15% to $8.79. The market value of their outstanding shares is at $11.5 million.
• Arrowhead Pharma (NASDAQ:ARWR) shares increased by 18.05% to $87.97. The company's market cap stands at $10.4 billion.
• Curis (NASDAQ:CRIS) stock moved upwards by 10.94% to $5.27. The market value of their outstanding shares is at $9.2 million.

Losers

• Trinity Biotech (NASDAQ:TRIB) stock declined by 26.5% to $0.26 during Wednesday's pre-market session. The market value of their outstanding shares is at $7.2 million.
• Picard Medical (AMEX:PMI) stock declined by 22.08% to $0.09. The market value of their outstanding shares is at $12.3 million.
• Jupiter Neurosciences (NASDAQ:JUNS) stock decreased by 19.39% to $0.14. The company's market cap stands at $8.1 million.
• Zhengye Biotechnology (NASDAQ:ZYBT) stock declined by 19.3% to $2.3. The company's market cap stands at $135.0 million.
• Catheter Precision (AMEX:VTAK) shares fell 17.8% to $0.41. The market value of their outstanding shares is at $1.7 million.
• Curanex Pharmaceuticals (NASDAQ:CURX) stock fell 10.98% to $0.18. The market value of their outstanding shares is at $5.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.